FGF19 specifically binds FGFR4 and high FGF19 expression or hyperactivation of FGF19/FGFR4 signalling in hepatocellular carcinoma (HCC) cells is responsible for the resistance to sorafenib, the only TK inhibitor approved for the treatment of this diseases [65]. Here, FGFR4 is linked to hepatocellular carcinoma.